Molly platform technology supports the launch of first commercial ustekinumab autoinjector in Europe

SHL Medical, a pioneering leader in self-injection solutions, announces another commercial launch of our Molly® modular platform autoinjector, now supporting Samsung Bioepis and the Sandoz Pyzchiva® autoinjector, the first commercially available autoinjector for an ustekinumab biosimilar in Europe. This milestone reflects the success of a strategic collaboration between SHL Medical, Samsung Bioepis, and Sandoz, bringing together expertise in patient-focused drug delivery, biosimilar development, and commercialization.

Ustekinumab is a monoclonal antibody targeting interleukin-12 and -23 (IL-12/23), approved for the treatment of multiple chronic inflammatory conditions, including plaque psoriasis, psoriatic arthritis, and Crohn’s disease. Pyzchiva, developed by Samsung Bioepis and launched in an autoinjector format by Sandoz, is the first ustekinumab biosimilar autoinjector to become commercially available in Europe, further strengthening Molly’s growing track record in supporting therapies across various disease areas. 

Supporting 21 approved combination products across 28+ indications, Molly is among the most widely adopted autoinjector platform technologies in the industry. Its modular design and proven performance help pharma partners reduce development risk, accelerate timelines, and support flexibility across device designs and production needs. Today, the Molly device supports a wide range of self-injection therapies, including autoimmune conditions, metabolic disorders, and the expanding field of obesity management.  

“This commercial launch demonstrates how our Molly autoinjector continues to support the delivery of leading therapies for chronic conditions in real-world settings,” said Markus Puusepp, Chief Growth Officer of SHL Medical. “We are proud to contribute to this important milestone and to work alongside partners like Sandoz and Samsung Bioepis, to deliver platform technology that meet both patient and market needs.” 

As self-injection becomes a defining mode of treatment for patients managing chronic diseases, SHL Medical continues advancing our mission to enable patients’ independence, working in close partnerships with pharma leaders like Sandoz and Samsung Bioepis, to bring reliable solutions designed for real-world use. To date, we’ve launched more than 50 single-use combination products with our partners—more than any other company in the industry.